Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Addeo · SciRah

Researcher profile · Semantic Scholar

A. Addeo

Share profile

A. Addeo — researcher profile on SciRah

h-index: 43
Works: 254
Citations: 6,200

Most-cited papers

Oncogenic alterations in advanced NSCLC: a molecular super-highway
A. Friedlaender, M. Pérol, G. Banna, K. Parikh +1 more
2024Biomarker Research133 citations Open access
Semantic Scholar
Novel targets for immune-checkpoint inhibition in cancer.
Maxime Borgeaud, J. Sandoval, M. Obeid, G. Banna +3 more
2023Cancer Treatment Reviews130 citations Open access
Semantic Scholar
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
G. Dy, R. Govindan, V. Velcheti, G. Falchook +20 more
2023Journal of Clinical Oncology123 citations Open access
Semantic Scholar
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
G. Banna, M. Hassan, A. Signori, E. Giunta +5 more
2024JAMA Network Open101 citations Open access
Semantic Scholar
Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review.
Maxime Borgeaud, K. Parikh, G. Banna, Floryane Kim +3 more
2024Journal of Thoracic Oncology73 citations Open access
Semantic Scholar
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
Annapaola Mariniello, Maxime Borgeaud, Marc Weiner, D. Frisone +2 more
2025BioDrugs60 citations Open access
Semantic Scholar
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
T. El Zarif, A. Nassar, E. Adib, Bailey G Fitzgerald +77 more
2023Journal of Clinical Oncology55 citations Open access
Semantic Scholar
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Maxime Borgeaud, Timothée Olivier, J. Bar, S. Saw +6 more
2025Ca49 citations Open access
Semantic Scholar
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer
U. Malapelle, N. Leighl, A. Addeo, D. Hershkovitz +12 more
2024British Journal of Cancer38 citations Open access
Semantic Scholar
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives
A. Addeo, Ernesto Miranda, P. den Hollander, A. Friedlaender +4 more
2023Pharmacology and Therapeutics38 citations Open access
Semantic Scholar
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.
G. Banna, Ornella Cantale, S. Muthuramalingam, J. Cave +13 more
2022International Immunopharmacology35 citations Open access
Semantic Scholar
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
O. Illini, H. Fabikan, A. Swalduz, A. Vikström +27 more
2022Therapeutic Advances in Medical Oncology33 citations Open access
Semantic Scholar
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
A. Cortellini, L. Brunetti, G. Di Fazio, E. Garbo +103 more
2025Journal for ImmunoTherapy of Cancer32 citations Open access
Semantic Scholar
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis
Shobana Anpalakhan, A. Signori, A. Cortellini, E. Verzoni +43 more
2023iScience28 citations Open access
Semantic Scholar
Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study
Hui-Ping Qiang, Yuqiong Lei, Yinchen Shen, Jiaqi Li +12 more
2022Translational Lung Cancer Research28 citations Open access
Semantic Scholar
Neoadjuvant Immunotherapy: A Promising New Standard of Care
Emma Boydell, J. L. Sandoval, O. Michielin, M. Obeid +2 more
2023International Journal of Molecular Sciences27 citations Open access
Semantic Scholar
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
D. König, S. Schär, D. Vuong, M. Guckenberger +18 more
2022ESMO Open26 citations Open access
Semantic Scholar
Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer.
D. Tavernari, M. Borgeaud, Ximeng Liu, P. Kaushal +3 more
2024Journal of Thoracic Oncology23 citations Open access
Semantic Scholar
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
A. Agbarya, W. Shalata, A. Addeo, A. Charpidou +8 more
2022Journal of Clinical Medicine22 citations Open access
Semantic Scholar
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study
M. Zheng, Yong Xia, K. Pan, F. Sun +32 more
2025Annals of Oncology21 citations Open access
Semantic Scholar
Biological Rationale for Peripheral Blood Cell–Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer
G. Banna, A. Friedlaender, M. Tagliamento, V. Mollica +8 more
2022Current Oncology Reports20 citations
Semantic Scholar
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
A. Schuler, J. Huser, S. Schmid, S. Schär +15 more
2023Lung Cancer17 citations
Semantic Scholar
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target.
G. Mountzios, S. P. Saw, L. Hendriks, J. Menis +9 more
2025Cancer Treatment Reviews16 citations Open access
Semantic Scholar
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis
Shobana Anpalakhan, P. Huddar, R. Behrouzi, A. Signori +15 more
2023Frontiers in Oncology15 citations Open access
Semantic Scholar
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Federica Pecci, Hui Li, A. Di Federico, Jia Wu +27 more
2025Clinical Cancer Research14 citations Open access
Semantic Scholar
SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial.
L. Mauti, T. Finazzi, L. Holer, A. Bettini +16 more
2023Journal of Clinical Oncology12 citations Open access
Semantic Scholar
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.
Matthias Guckenberger, I. Opitz, T. Dellaporta, Alessandra Curioni-Fontecedro +21 more
2025Lung Cancer11 citations Open access
Semantic Scholar
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
O. Illini, F. Saalfeld, P. Christopoulos, M. Duruisseaux +44 more
2024International Journal of Molecular Sciences11 citations Open access
Semantic Scholar
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
L. Cantini, F. Paoloni, Federica Pecci, F. Spagnolo +47 more
2023Journal of the National Cancer Institute10 citations Open access
Semantic Scholar
Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors
J. Rodon, N. Yamamoto, Toshihiko Doi, F. Ghiringhelli +16 more
2023Molecular Cancer Therapeutics10 citations Open access
Semantic Scholar
The risk of lung cancer from vaping or e-cigarette usage: a systematic review
S. Mohapatra, A. Tiwari, A. Kandala, R. Winayak +14 more
2025ESMO Open9 citations Open access
Semantic Scholar
The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
Maxime Borgeaud, Floryane Kim, A. Friedlaender, F. Lococo +2 more
2023Journal of Clinical Medicine9 citations Open access
Semantic Scholar
Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods
A. Fuster-Matanzo, A. Picó-Peris, F. Bellvís-Bataller, A. Jimenez-Pastor +9 more
2025European Radiology8 citations Open access
Semantic Scholar
Thymic Epithelial Tumors: What’s new and what’s next?
M. Imbimbo, G. Salfi, Maxime Borgeaud, Margaret Ottaviano +4 more
2025ESMO Rare Cancers7 citations Open access
Semantic Scholar
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?
S. Cheo, Molly S. C. Li, D. Huang, S. P. Saw +5 more
2025Cancer Treatment Reviews7 citations Open access
Semantic Scholar
Liquid biopsy: An innovative tool in oncology. Where do we stand?
Serafina Martella, D. Wekking, E. Lai, M. Lambertini +8 more
2025Seminars in Oncology7 citations
Semantic Scholar
Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis
Jonathan N. Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes, I. Michelon +10 more
2024JCO Precision Oncology7 citations Open access
Semantic Scholar
Management of stage III non-small-cell lung cancer: rays of hope
Floryane Kim, Maxime Borgeaud, A. Addeo, A. Friedlaender
2024Exploration of Targeted Anti-tumor Therapy7 citations Open access
Semantic Scholar
Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer
Nathalie Baudoux, A. Friedlaender, A. Addeo
2023Clinical Medicine Insights: Oncology7 citations Open access
Semantic Scholar
Cellular Therapy in NSCLC: Between Myth and Reality
M. Imbimbo, Laureline Wetterwald, A. Friedlaender, K. Parikh +1 more
2023Current Oncology Reports7 citations Open access
Semantic Scholar
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
Shobana Anpalakhan, P. Huddar, R. Behrouzi, A. Signori +13 more
2023International Journal of Molecular Sciences7 citations Open access
Semantic Scholar
The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation
H. R. Howard, M. Hasanova, A. Tiwari, A. Ghose +17 more
2025ESMO Open6 citations Open access
Semantic Scholar
Lung Cancer in Switzerland.
R. Werner, A. Curioni-Fontecedro, L. Mauti, A. Addeo +10 more
2024Journal of Thoracic Oncology6 citations
Semantic Scholar
ADRIATIC: When face value is enough.
A. Addeo, Stephen V. Liu
2024i Medicina6 citations
Semantic Scholar
Prediction of oncogene mutation status in non-small cell lung cancer: A systematic review and meta-analysis with a special focus on artificial-intelligence-based methods
A. Fuster-Matanzo, A. Picó-Peris, F. Bellvís-Bataller, A. Jimenez-Pastor +6 more
2024medRxiv6 citations Open access
Semantic Scholar
First-line immunotherapy in non-small cell lung cancer: how to select and where to go
A. Mogavero, Ornella Cantale, V. Mollica, Shobana Anpalakhan +6 more
2023Expert Review of Respiratory Medicine6 citations
Semantic Scholar
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.
R. Soo, K. Vervita, M. Früh, B. Cho +22 more
2025Lung Cancer5 citations Open access
Semantic Scholar
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
J. Parekh, K. Parikh, J. Reuss, A. Friedlaender +1 more
2023Current Oncology Reports5 citations Open access
Semantic Scholar
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial
A. M. da Silva Lopes, S. Colomer-Lahiguera, Célia Darnac, Stellio Giacomini +11 more
2023JMIR Research Protocols5 citations Open access
Semantic Scholar
Development and validation of a DNA damage repair-related gene-based prediction model for the prognosis of lung adenocarcinoma
C. Qin, Xiaodong Fan, X. Sai, Bo Yin +4 more
2023Journal of Thoracic Disease5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Banna×15
Invite
G. Banna — researcher profile on SciRah
A. Friedlaender×12
Invite
A. Friedlaender — researcher profile on SciRah
A. Cortellini×8
Invite
A. Cortellini — researcher profile on SciRah
Maxime Borgeaud×7
Invite
Maxime Borgeaud — researcher profile on SciRah

×5

Invite

A. Signori — researcher profile on SciRah

Shobana Anpalakhan×5

Invite

Shobana Anpalakhan — researcher profile on SciRah

Invite

D. Pinato — researcher profile on SciRah

Floryane Kim×4

Invite

Floryane Kim — researcher profile on SciRah

Invite

M. Früh — researcher profile on SciRah

O. Michielin×3

Invite

O. Michielin — researcher profile on SciRah

Invite

C. Genova — researcher profile on SciRah

Invite

J. Bar — researcher profile on SciRah